These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18024384)

  • 21. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis.
    Onozawa M; Hashino S; Sogabe S; Haneda M; Horimoto H; Izumiyama K; Kondo T; Aldana LP; Hamada K; Asaka M
    J Clin Oncol; 2005 Apr; 23(10):2425-6. PubMed ID: 15800335
    [No Abstract]   [Full Text] [Related]  

  • 22. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas.
    Wu KL; Helgason HH; van der Holt B; Wijermans PW; Lokhorst HM; Smit WM; Sonneveld P
    Leukemia; 2005 Jan; 19(1):143-5. PubMed ID: 15510202
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro study of the hypercoagulable state in multiple myeloma patients treated or not with thalidomide.
    Petropoulou AD; Gerotziafas GT; Samama MM; Hatmi M; Rendu F; Elalamy I
    Thromb Res; 2008; 121(4):493-7. PubMed ID: 17618677
    [No Abstract]   [Full Text] [Related]  

  • 24. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
    Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
    Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment.
    Prescrire Int; 2009 Apr; 18(100):49-52. PubMed ID: 19585712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
    Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
    Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
    Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
    Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide-associated gynecomasty in a patient with multiple myeloma.
    Pulik M; Genet P; Lionnet F; Touahri T
    Am J Hematol; 2002 Jul; 70(3):265. PubMed ID: 12111777
    [No Abstract]   [Full Text] [Related]  

  • 30. Severe tremors associated with use of thalidomide.
    Chiruka S; Chapman CS
    Am J Hematol; 2005 Jan; 78(1):81-2. PubMed ID: 15609275
    [No Abstract]   [Full Text] [Related]  

  • 31. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
    Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
    J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
    [No Abstract]   [Full Text] [Related]  

  • 32. Interstitial granulomatous drug reaction due to thalidomide.
    Yazganoğlu KD; Tambay E; Mete O; Ozkaya E
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):490-3. PubMed ID: 19335735
    [No Abstract]   [Full Text] [Related]  

  • 33. [Interstitial pneumonitis as an adverse effect of thalidomide].
    Scholte JB; Potjewijd J; Voogt PJ; Custers FL; Lie KS
    Ned Tijdschr Geneeskd; 2009; 153():A452. PubMed ID: 19785872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile.
    Hattori Y; Okamoto S; Shimada N; Kakimoto T; Morita K; Tanigawara Y; Ikeda Y
    Cancer Sci; 2008 Jun; 99(6):1243-50. PubMed ID: 18384432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
    Smith SM; Grinblatt D; Johnson JL; Niedzwiecki D; Rizzieri D; Bartlett NL; Cheson BD;
    Br J Haematol; 2008 Feb; 140(3):313-9. PubMed ID: 18217897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoimmune thyroiditis during thalidomide treatment.
    Erdem F; Gundogdu M; Kiki I; Capoĝlu I
    Am J Hematol; 2006 Feb; 81(2):152. PubMed ID: 16432860
    [No Abstract]   [Full Text] [Related]  

  • 37. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making.
    Potenza L; Luppi M; Morselli M; Saviola A; Ferrari A; Riva G; Longo G; Marietta M; Torelli G
    Thromb Haemost; 2004 Apr; 91(4):834-6. PubMed ID: 15045155
    [No Abstract]   [Full Text] [Related]  

  • 40. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
    Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
    Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.